Euro vs US Dollar

Registrieren Sie sich, um in unseren aktiven Foren mit gleichgesinnten Anlegern zu diskutieren.

Registrieren

ENLV Enlivex Therapeutics Ltd

1,16

0,00 (0,00%)

Nach Börsenschluss

Zuletzt aktualisiert: 22:21:21

Verzögert um 15 Minuten

Form SC 13G - Statement of Beneficial Ownership by Certain Investors

null

Enlivex Therapeutics (NASDAQ:ENLV)
Historical Stock Chart
Von Feb 2025 bis Mär 2025

Click Here for more Enlivex Therapeutics Charts.

Enlivex Therapeutics (NASDAQ:ENLV)
Historical Stock Chart
Von Mär 2024 bis Mär 2025

Click Here for more Enlivex Therapeutics Charts.

News Enlivex Therapeutics Ltd

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
Dienstag 4 März 2025 (1 Woche vor) • Edgar (US Regulatory)

Enlivex Therapeutics Announces Investor Webinar to Discuss Positive Interim Data from Phase I/II Allocetra™ Trial in Knee Osteoarthritis
Dienstag 4 März 2025 (1 Woche vor) • GlobeNewswire Inc.

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
Montag 3 März 2025 (1 Woche vor) • Edgar (US Regulatory)

Enlivex Announces Positive Interim Data – Statistically Significant 47.0% Durable and Persistent Pain Reduction At Six Months, in Patients with Moderate to Severe Knee Osteoarthritis
Montag 3 März 2025 (1 Woche vor) • GlobeNewswire Inc.

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
Dienstag 18 Februar 2025 (3 Wochen vor) • Edgar (US Regulatory)

Enlivex Issues Urgent Statement on Fraudulent News Dissemination
Dienstag 18 Februar 2025 (3 Wochen vor) • GlobeNewswire Inc.

Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
Freitag 14 Februar 2025 (4 Wochen vor) • Edgar (US Regulatory)

Enlivex Receives Regulatory Authorization for the Initiation of a Phase I Trial Evaluating Allocetra in Patients with TMJ Osteoarthritis
Mittwoch 11 Dezember 2024 (3 Monate vor) • GlobeNewswire Inc.

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
Dienstag 3 Dezember 2024 (3 Monate vor) • Edgar (US Regulatory)

Enlivex Announces Positive Interim Efficacy Data from Allocetra Trial in Patients with Moderate to Severe Knee Osteoarthritis
Dienstag 3 Dezember 2024 (3 Monate vor) • GlobeNewswire Inc.

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
Freitag 29 November 2024 (3 Monate vor) • Edgar (US Regulatory)

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
Mittwoch 20 November 2024 (4 Monate vor) • Edgar (US Regulatory)

Weitere Enlivex Therapeutics Ltd News-Artikel

Euro vs US Dollar

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen